Add BrightSurf on Google Email

New England Journal of Medicine publishes outcomes from practice-changing E1910 trial for patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia

The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.

SourceECOG-ACRIN Cancer Research Group·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJul 24, 2024

Research spotlight: Patterns and prognostications in immune-related adverse events from immunotherapy treatment

A study comprehensively evaluated occurrence patterns of immune-related adverse events, including those affecting single organs and multiple organs. Researchers found that most events tend to co-occur and identified seven patient clusters with different development patterns, which were associated with improved or worsened survival outc...

SourceMassachusetts General Hospital·JournalThe Lancet Oncology·TypeData/statistical analysis·DateJul 16, 2024

Breaking down barriers: ROCK2 inhibition facilitates drug delivery in fibrotic pancreatic cancer

Researchers developed a human pancreatic cancer fibrotic barrier model to assess treatment strategies and test efficacy of therapeutic interventions. Inhibition of ROCK2 pathway resulted in reduced ECM remodeling and improved tissue permeability for drugs, highlighting its potential for enhancing drug delivery in PDAC.

SourceOkayama University·JournalJournal of Controlled Release·TypeExperimental study·DateJun 5, 2024

Body’s ‘message in a bottle’ delivers targeted cancer treatment

A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...

SourceKarolinska Institutet·JournalNature Biomedical Engineering·TypeExperimental study·DateMay 20, 2024

Expanding a lymph node, boosting a vaccine

Researchers from Wyss Institute and Harvard University developed a biomaterial vaccine that enhances and sustains lymph node expansion, leading to more effective anti-tumor responses. The vaccine formulation, based on microscale mesoporous silica rods, reprograms antigen-presenting cells to orchestrate complex immune responses.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Biomedical Engineering·TypeExperimental study·DateMay 6, 2024

McMaster researchers create first-ever guidelines to help kids build tolerance to food allergens

The McMaster University research team created the first-ever guidelines for preparing families to build their child's tolerance to common food allergens through oral immunotherapy. The guidelines, published in the Journal of Allergy and Clinical Immunology, standardize the preparation process and provide a consent form template.

SourceMcMaster University·JournalJournal of Allergy and Clinical Immunology·DateApr 8, 2024

An immunotherapy to overcome resistant leukemia

Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.

SourceUniversity of Zurich·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 21, 2024

Empty “backpacks” activate the immune system against cancer

Researchers have demonstrated that attaching 'empty' backpacks to neutrophils activates them against cancer. The treated neutrophils infused into mice with cancer activated other immune cells and reduced tumor size. This technique is attractive as a 'drug-free' cell therapy for cancer.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Biomedical Engineering·TypeExperimental study·DateMar 19, 2024

Progress in developing specific immunotherapies for type 1 diabetes

Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.

SourceGermans Trias i Pujol Research Institute·JournalJournal of Autoimmunity·TypeExperimental study·DateMar 18, 2024

A safer treatment path for high-risk children to overcome food allergies

A new study from the University of British Columbia has found that sublingual immunotherapy (SLIT) is safe and effective for older children with multiple food allergies, who cannot risk consuming allergens orally. The treatment involves placing smaller amounts of food allergens under the tongue, allowing patients to build up their resi...

SourceUniversity of British Columbia·JournalJournal of Allergy and Clinical Immunology·TypeExperimental study·DateFeb 28, 2024

New clinical practice guideline provides evidence-based recommendations for immunotherapy for inhalant allergy

The American Academy of Otolaryngology has released a new clinical practice guideline supporting clinicians with evidence-based recommendations on immunotherapy for inhalant allergies. The guideline provides 12 key action statements to guide treatment, aiming to optimize patient care and reduce unnecessary variation in management.

Chronic stress spreads cancer … here’s how

A recent study by Cold Spring Harbor Laboratory researchers reveals that chronic stress can increase cancer's ability to spread. By mimicking chronic stress in mice with cancer, the team discovered that stress causes neutrophils to form sticky web-like structures called NETs, making body tissues more susceptible to metastasis.

SourceCold Spring Harbor Laboratory·JournalCancer Cell·DateFeb 22, 2024

The immune system’s moonlighters

Researchers have found a new potential therapeutic target for autoimmune diseases such as lupus and multiple sclerosis by identifying an overlooked sequence in the IκBζ protein. This sequence, known as the OCA peptide, can activate key proteins in immune cells and may help reeling in immune cells gone haywire.

SourceCold Spring Harbor Laboratory·JournalMolecular Cell·DateFeb 20, 2024

Researchers uncover on/off switch for breast cancer metastasis

A Stanford University study reveals that ENPP1 is produced by both cancer cells and healthy cells around tumors, with high levels linked to immunotherapy resistance and metastases. Researchers found that targeting ENPP1 could improve patient responses to existing medicines and help clinicians better predict patient outcomes

SourceStanford University·JournalProceedings of the National Academy of Sciences·DateDec 20, 2023

Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial

A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.

SourceMalaghan Institute of Medical Research·JournalBlood·TypeExperimental study·DateDec 11, 2023

World-first trial offers new hope for type 1 diabetes

A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...

SourceSt Vincent's Institute of Medical Research·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 6, 2023

Hope for autoimmune skin disorder sufferers with new immunotherapy strategy

Researchers discovered distinct mechanisms controlling different types of immune cells and found a way to selectively eliminate 'problematic' cells driving autoimmune disorders. This breakthrough offers precise targets for potential treatment strategies, potentially revolutionizing the way we treat skin conditions.

SourceThe Peter Doherty Institute for Infection and Immunity·JournalScience·TypeExperimental study·DateNov 30, 2023

Case study: overcoming barriers to venom immunotherapy for fire ant allergy patients

A recent case study highlights the challenges faced by families seeking venom immunotherapy for fire ant allergies, particularly in low-income communities. Despite proven safety and effectiveness of treatment, access remains a significant issue due to transportation barriers, lack of childcare, and work constraints.

SourceOchsner Health System·JournalJournal of Allergy and Clinical Immunology·DateAug 23, 2023

Combination therapy effective against canine melanoma

A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.

SourceHokkaido University·JournalCancers·TypeRandomized controlled/clinical trial·DateJun 22, 2023